{"id":"crisaborole-vehicle","safety":{"commonSideEffects":[{"rate":"approximately 25-30%","effect":"Application site burning"},{"rate":"approximately 10-15%","effect":"Application site pain"},{"rate":"approximately 5-10%","effect":"Skin irritation"}]},"_chembl":{"chemblId":"CHEMBL484785","moleculeType":"Small molecule","molecularWeight":"251.05"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Crisaborole Vehicle","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:59:55.898901+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T04:00:12.733537+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T04:00:02.826176+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Crisaborole Vehicle","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T04:00:03.805212+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Phosphodiesterase 4 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:00:04.486530+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL484785/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:00:04.382065+00:00"}},"_dailymed":null,"aiSummary":"Crisaborole, marketed by Pfizer, is a topical medication with a key composition patent expiring in 2028. Its primary strength lies in its unique mechanism of action, which differentiates it in the market. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.","mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Crisaborole inhibits phosphodiesterase 4, an enzyme that regulates immune cell function and inflammatory responses. By blocking PDE4, it increases intracellular cAMP levels, which suppresses the production of pro-inflammatory cytokines and reduces skin inflammation characteristic of atopic dermatitis. This mechanism allows for topical anti-inflammatory activity without systemic corticosteroid effects.","oneSentence":"Crisaborole is a phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in atopic dermatitis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:23.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T04:00:12.734813+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Atopic dermatitis (mild to moderate)"}]},"trialDetails":[{"nctId":"NCT05200403","phase":"PHASE4","title":"Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis","status":"TERMINATED","sponsor":"Boston University","startDate":"2022-07-26","conditions":"Atopic Dermatitis","enrollment":72},{"nctId":"NCT03832010","phase":"PHASE4","title":"Steroid-reducing Effects of Crisaborole","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2019-12-17","conditions":"Atopic Dermatitis, Eczema","enrollment":24},{"nctId":"NCT05298033","phase":"PHASE2","title":"Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2022-09-07","conditions":"Vitiligo","enrollment":32},{"nctId":"NCT04040192","phase":"PHASE3","title":"A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-09-12","conditions":"Atopic Dermatitis","enrollment":620},{"nctId":"NCT04360187","phase":"PHASE3","title":"Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-07-27","conditions":"Atopic Dermatitis","enrollment":391},{"nctId":"NCT04091087","phase":"PHASE2","title":"Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-26","conditions":"Stasis Dermatitis","enrollment":66},{"nctId":"NCT03539601","phase":"PHASE4","title":"A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-04-27","conditions":"Atopic Dermatitis","enrollment":237},{"nctId":"NCT03868098","phase":"PHASE4","title":"Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2019-05-21","conditions":"Dermatitis, Atopic","enrollment":31},{"nctId":"NCT03954158","phase":"PHASE2","title":"Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-06-15","conditions":"Atopic Dermatitis","enrollment":81},{"nctId":"NCT03233529","phase":"PHASE2","title":"Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-07-31","conditions":"Dermatitis, Atopic","enrollment":40},{"nctId":"NCT03760042","phase":"PHASE1","title":"Study To Assess Local Tolerability of Crisaborole 2% Ointment and Vehicle Ointment In Healthy Participants Using Subject-reported Assessments and Objective Measurements","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-11-14","conditions":"Healthy","enrollment":32},{"nctId":"NCT01258088","phase":"PHASE1","title":"Safety Study of Ointment for the Treatment of Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-11-30","conditions":"Plaque-type Psoriasis","enrollment":16},{"nctId":"NCT03260595","phase":"PHASE1","title":"A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-09-13","conditions":"Healthy, Atopic Dermatitis","enrollment":32},{"nctId":"NCT00763204","phase":"PHASE1","title":"A Phase I Study to Assess Novel Cream in a Psoriasis Plaque Test","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-02-29","conditions":"Psoriasis","enrollment":12},{"nctId":"NCT00762658","phase":"PHASE1","title":"A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-11-30","conditions":"Psoriasis","enrollment":12},{"nctId":"NCT01301508","phase":"PHASE2","title":"Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-05","conditions":"Dermatitis, Atopic","enrollment":46},{"nctId":"NCT01300052","phase":"PHASE2","title":"AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-01-26","conditions":"Psoriasis","enrollment":68},{"nctId":"NCT01029405","phase":"PHASE2","title":"Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-11","conditions":"Psoriasis","enrollment":145},{"nctId":"NCT00755196","phase":"PHASE2","title":"Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-09","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT02118766","phase":"PHASE3","title":"Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03","conditions":"Dermatitis, Atopic","enrollment":763},{"nctId":"NCT02118792","phase":"PHASE3","title":"Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03","conditions":"Dermatitis, Atopic","enrollment":764},{"nctId":"NCT00759161","phase":"PHASE2","title":"Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-11","conditions":"Psoriasis","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL484785"},"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Crisaborole Vehicle","genericName":"Crisaborole Vehicle","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T04:00:12.734813+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}